{"id":"NCT02698566","sponsor":"Genentech, Inc.","briefTitle":"A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)","officialTitle":"An Open-Label, Single-Arm Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration or Macular Edema Secondary to Retinal Vein Occlusion to Evaluate the Usability of Lucentis® 0.5 mg Prefilled Syringe","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-21","primaryCompletion":"2016-04-05","completion":"2016-04-05","firstPosted":"2016-03-03","resultsPosted":"2017-07-26","lastUpdate":"2017-09-21"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Macular Edema"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":["Lucentis"]}],"arms":[{"label":"Ranibizumab PFS","type":"EXPERIMENTAL"}],"summary":"This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.","primaryOutcome":{"measure":"Percentage of Successful Task Completions","timeFrame":"Day 1","effectByArm":[{"arm":"Ranibizumab PFS","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":15},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["29853609"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Conjunctival hemorrhage"]}}